C&EN eBook
Leveraging advanced analytical tools to de-risk pharmaceutical development
Brought to you by Lonza Small Molecules

Drug development continues to advance understanding about causes of disease as well as to innovate therapeutic modalities. Yet the process remains time intensive, costly, and high risk. The average drug takes over 10 years and $1 billion–$2 billion to be approved for clinical use— yet 90% of new drugs reaching Phase I clinic al trials ultimately fail to reach approval.

This high risk of failure, along with the substantial investment of time, labor, and financial resources put into every new drug candidate, poses a persistent challenge for drug developers. To ensure the efficient use of development resources and the creation of safe, effective, and reliable products for patients, drugmakers must take steps to de-risk development at every step. In this e-book, learn about three tools that drug developers can use to successfully navigate the journey from candidate compound to clinical success.

Key Objectives:
  • How solid form screening is useful at development stages from lead form identification to intellectual property protection
  • How physiologically based pharmacokinetic (PBPK) modeling provides a deeper view into how a drug behaves in the body while accounting for patient variability
  • How including real word supply chain information in a retrosynthetic analysis can deliver synthetic routes with reduced cost and risk

Brought to you by:
Lonza Small Molecules
Please complete the form to download the eBook.
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

Copyright © 2023 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy